Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DMAC | US
-0.07
-1.20%
Healthcare
Biotechnology
30/06/2024
02/06/2026
5.77
5.76
5.89
5.54
DiaMedica Therapeutics Inc. a clinical stage biopharmaceutical company develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199 a recombinant human tissue kallikrein-1 protein which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis Minnesota.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
51.2%1 month
51.5%3 months
48.0%6 months
52.0%-
-
3.43
0.01
0.01
-0.96
-
-
-22.35M
246.65M
246.65M
-
-
-
-
-35.18
2.37
0.52
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.94
Range1M
1.13
Range3M
2.63
Rel. volume
0.90
Price X volume
874.92K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 8.42 | 270.15M | -1.06% | n/a | -186.13% |
| Rocket Pharmaceuticals Inc | RCKT | Biotechnology | 2.89 | 262.92M | -4.30% | n/a | 6.71% |
| Northwest Biotherapeutics Inc | NWBO | Biotechnology | 0.205 | 256.92M | -7.11% | n/a | 0.00% |
| Moolec Science SA Ordinary Shares | MLEC | Biotechnology | 6.83 | 255.86M | -0.29% | n/a | 209.19% |
| Enanta Pharmaceuticals Inc | ENTA | Biotechnology | 12.03 | 254.90M | -5.05% | n/a | 151.88% |
| MacroGenics Inc | MGNX | Biotechnology | 4.05 | 254.02M | -2.17% | n/a | 58.90% |
| Solid Biosciences Inc | SLDB | Drug Manufacturers-Specialty & Generic | 6.58 | 253.96M | -8.48% | n/a | 13.09% |
| Verrica Pharmaceuticals Inc | VRCA | Biotechnology | 5.79 | 247.05M | -1.86% | n/a | -348.20% |
| Entrada Therapeutics Inc. Common Stock | TRDA | Biotechnology | 6.64 | 247.01M | -3.91% | 5.77 | 14.99% |
| Abeona Therapeutics Inc | ABEO | Biotechnology | 5.69 | 246.46M | 1.07% | n/a | 31.63% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Urban One Inc | UONEK | Broadcasting - Radio | 4.7 | 249.14M | -10.36% | n/a | 268.43% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 16.74 | 186.78M | -0.42% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 11.36 | 182.41M | 2.53% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 40.57 | 116.51M | -0.44% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.01 | 97.90M | 0.84% | 9.09 | 39.79% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 7.09 | 67.49M | 2.75% | n/a | 19.98% |
| ILAG | ILAG | Building Products & Equipment | 3.6016 | 65.04M | -4.21% | n/a | 5.48% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 9.37 | 58.67M | -0.64% | 14.48 | 7.10% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 19.59 | 29.83M | 25.34% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.11 | 16.22M | -2.63% | 0.03 | 16.03% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.96 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.43 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 48.04 | - | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 246.65M | - | Emerging |